CLPT

ClearPoint Neuro Inc. (CLPT)
Healthcare • Medical Devices • $15.15 • MCap: 454,341,888 🌐
https://www.clearpointneuro.com • ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula. It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform. In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting. It has licenses and collaboration agreements with Koninklijke Philips N.V., UCB Biopharma SRL, Clinical Laserthermia Systems AB, University of California, San Francisco, and NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Buy Decision Core
Total Score
40
Business Quality
10
Financial Strength
10
Growth Outlook
1
Momentum
4
Price Action
Current
15.15
52W High
29.60
52W Low
8.66
Above 50DMA
14.57 (3.97%)
Above 200DMA
14.78 (2.48%)
Relative Strength
Relative Strength
0.17
RS 3M
0.44
RS 6M
-0.02
RS 9M
-0.42
RS 12M
0.38
Fundamentals
Revenue Growth
0.43%
Earnings Growth
0%
ROE
-1.50%
ROA
-0.25%
Valuation
PE (Fwd)
-16.12
PEG
0.61
P/B
24.12
Upside
87.02%
Risk
Beta
1.24
Short %
0.15
Risk Score
5.00
Analyst
Rating
none
Target
28.33
Beta
1.24
Analysts
0


Total Score
40
Upside
87.02%
Relative Strength
0.17
Beta
1.24
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Trading above 50 DMA
  • Trading above 200 DMA
  • Analyst upside exceeds 15%
Key Risks
  • Negative ROE
Score Breakdown
Business
10
Financial
10
Growth
1
Valuation
10
Risk
2
Momentum
4
Technical
52W High: 29.60
52W Low: 8.66
Above 50DMA: 3.97%
Above 200DMA: 2.48%
Valuation
Forward PE: -16.12
PEG: 0.61
P/B: 24.12
Upside: 87.02%
Risk
Beta: 1.24
Short Float: 0.15%
ROE: -1.50%
ROA: -0.25%